Sanofi wins EU green light for new MS drug Lemtrada

LONDON, June 28 Fri Jun 28, 2013 7:32am EDT

Related Topics

LONDON, June 28 (Reuters) - French firm Sanofi has won a European green light for its new multiple sclerosis medicine Lemtrada, after a quarter-century drug development saga.

Lemtrada, also known as alemtuzumab, has been studied in multiple sclerosis (MS) since the early 1990s but its progress to market as a treatment for the disease has been halting and the drug has changed hands many times.

The European Medicines Agency said on Friday it was recommending Lemtrada for relapsing-remitting MS. EMA decisions are usually endorsed by the European Commission within a couple of months. (Reporting by Rosalba O'Brien and Caroline Copley)


After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.